PRINCETON, N.J., May 08, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming ...

In preclinical ferret studies, Infectimune ® based universal flu vaccines, comprised of PDS Biotech-licensed computationally optimized broadly reactive antigens (COBRAs), neutralized and protected ...

BioPharm International® spoke with Lun Xin, associate director at WuXi Biologics, about high-concentration biologics and some of the biggest challenges associated with their formulation.

Q1 2025 Earnings Call Transcript May 6, 2025 Krystal Biotech, Inc. misses on earnings expectations. Reported EPS is $1.2 EPS, expectations were $1.38. Operator: Thank you for standing by, and welcome ...

Story May 1 - Arvinas: After Arvinas announced during its Q1 results presentation that the biotech and partner Pfizer are dropping two phase 3 trials from their estrogen receptor degrader R&D plan ...

Q1 2025 Earnings Call Transcript May 8, 2025 Alpha Teknova, Inc. beats earnings expectations. Reported EPS is $-0.09, ...

and data readouts and presentations, as well as anticipated timelines; the potential benefits, safety and efficacy of Vir Biotechnology’s investigational therapies; Vir Biotechnology’s ...

Details of the presentation a Update on American Association for Cancer Research Annual Meeting 2025 presentationPRINCETON, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation ...

03, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq ... Song, MD, Chairman and CEO of NKGen, will participate in a virtual presentation and one-on-one meetings at the H.C. Wainwright 26th ...

At a time when investment has been low in biotech, establishing and maintaining good relationships with investors is vital.

Nanobiotix announces full results from completed phase 1 study evaluating JNJ-1900 (NBTXR3) in pancreatic cancer: Paris Tuesday, May 6, 2025, 11:00 Hrs [IST] Nanobiotix, a late-st ...